Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA (2016 - 2025)

Historic EBITDA for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$34.3 million.

  • Viridian Therapeutics, Inc.\DE's EBITDA rose 5439.01% to -$34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 1813.91%. This contributed to the annual value of -$270.3 million for FY2024, which is 1404.65% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's EBITDA stood at -$34.3 million, which was up 5439.01% from -$100.9 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year EBITDA high stood at -$14.0 million for Q3 2021, and its period low was -$100.9 million during Q2 2025.
  • Moreover, its 5-year median value for EBITDA was -$47.6 million (2023), whereas its average is -$49.4 million.
  • Examining YoY changes over the last 5 years, Viridian Therapeutics, Inc.\DE's EBITDA showed a top increase of 6793.39% in 2021 and a maximum decrease of 17902.1% in 2021.
  • Viridian Therapeutics, Inc.\DE's EBITDA (Quarter) stood at -$29.1 million in 2021, then crashed by 55.45% to -$45.2 million in 2022, then plummeted by 46.92% to -$66.5 million in 2023, then dropped by 21.38% to -$80.7 million in 2024, then surged by 57.47% to -$34.3 million in 2025.
  • Its EBITDA stands at -$34.3 million for Q3 2025, versus -$100.9 million for Q2 2025 and -$86.7 million for Q1 2025.